EYPT

SEC source: 0001562180-24-001050 · primarydocument.xml · nonDerivative · entry 2

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,962

SEC source: 0001562180-24-001050 · primarydocument.xml · nonDerivative · entry 1

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000785 · primarydocument.xml · derivative · entry 6

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,742

Underlying: Common Stock · 16,413 shares

Expires 2033-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000785 · primarydocument.xml · derivative · entry 5

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,721

Underlying: Common Stock · 9,604 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000785 · primarydocument.xml · nonDerivative · entry 4

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,962

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000785 · primarydocument.xml · nonDerivative · entry 3

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,566

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000785 · primarydocument.xml · nonDerivative · entry 2

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000785 · primarydocument.xml · nonDerivative · entry 1

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 9

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,026

Underlying: Common Stock · 15,609 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 8

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,588

Underlying: Common Stock · 33,665 shares

Expires 2031-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 7

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,253

Underlying: Common Stock · 51 shares

Expires 2031-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 6

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,505

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 5

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,170

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 4

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,779

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,114

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000673 · primarydocument.xml · derivative · entry 12

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,155

Underlying: Common Stock · 300 shares

Expires 2033-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000673 · primarydocument.xml · derivative · entry 11

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,325

Underlying: Common Stock · 300 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 8

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,962

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 7

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,262

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 6

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 5

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000784 · primarydocument.xml · derivative · entry 6

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,635

Underlying: Common Stock · 300 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000784 · primarydocument.xml · derivative · entry 5

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,304

Underlying: Common Stock · 300 shares

Expires 2031-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 4

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,505

SEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 3

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,805

SEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,105

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000636 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: Plan reported

Ownership: Indirect · By Family Trust

Disclosed balance after: 112,700

Underlying: Common Stock · 112,700 shares

Expires 2033-01-05

F4 · kind: On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company.

F5 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-000636 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 338,100

Underlying: Common Stock · 112,700 shares

Expires 2033-01-05

F4 · kind: On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company.

F5 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000636 · primarydocument.xml · nonDerivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,441

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 12

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,935

Underlying: Common Stock · 5,651 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 11

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,604

Underlying: Common Stock · 5,600 shares

Expires 2031-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 8

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,505

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 7

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,156

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 6

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 5

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000673 · primarydocument.xml · derivative · entry 10

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,455

Underlying: Common Stock · 5,700 shares

Expires 2033-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000673 · primarydocument.xml · derivative · entry 9

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,625

Underlying: Common Stock · 5,600 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 4

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,962

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 3

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,562

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 2

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000673 · primarydocument.xml · nonDerivative · entry 1

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000581 · primarydocument.xml · derivative · entry 12

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,155

Underlying: Common Stock · 500 shares

Expires 2033-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

SEC source: 0001562180-24-000581 · primarydocument.xml · derivative · entry 11

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,225

Underlying: Common Stock · 400 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020

SEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 8

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,962

SEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 7

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,462

SEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 6

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,862

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 5

Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,362

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.